Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000150195 | SCV000197117 | pathogenic | Non-small cell lung carcinoma; Neoplasm of the large intestine | 2013-06-20 | criteria provided, single submitter | clinical testing | The Thr599dup variant has been observed in a number of tumor types, including an aplastic thyroid carcinoma, melanoma, pancreatic adenocarcinoma and pilocytic as trocytomas (Jones 2009, Kubo 2009, Yu 2009, Eisenhardt 2011, Gauchotte 2011, Lon g 2011, Menzies 2012). In addition, it has been reported to have similar kinase activity as the BRAF Val600Glu variant (Eisenhardt 2011). |
Ce |
RCV001091496 | SCV001247574 | pathogenic | not provided | 2019-04-01 | criteria provided, single submitter | clinical testing | |
Institute for Genomic Medicine, |
RCV000515781 | SCV000611854 | pathogenic | Childhood ganglioglioma | 2017-10-09 | no assertion criteria provided | research | The duplication of three nucleotides (c.1794_1796TAC) is a nonframeshift variant that results in addition of a Threonine residue between Thr599 and Val600 in BRAF. In vitro studies of this variant demonstrated an increased kinase activity and cellular MEK/ERK activation potential comparable to that of BRAF V600E (Eisenhardt et al., 2011). Presumably, the insertion of an additional Threonine residue at this position destabilizes the inactive conformation of the BRAF kinase domain. |
Department of Pathology and Laboratory Medicine, |
RCV001091496 | SCV001553093 | uncertain significance | not provided | no assertion criteria provided | clinical testing |